Avita Medical: Pioneering the Paradigm Shift in Skin Regeneration

May 17th, 2019

By Blackcrane Capital’s Investment Team

For the better part of the last 25 years, there have been no meaningful advancements in the treatment paradigm for burn victims. Of the nearly 500,000 burn victims annually in the US, many must deal with two very different types of injuries: external scars that limit their physical capabilities and psychological scars that can often deprive individuals of their ambitions.

For the first time, thanks to the efforts of renowned surgeon Dr. Fiona Wood and her scientific collaborator, Marie Stoner, there is a medical breakthrough that is making it possible for burn patients to regenerate their damaged skin more effectively, all while reducing the length of their recovery.

In this commentary, the Blackcrane Capital Investment Team evaluates Avita Medical and investigates how the company’s RECELL product is changing the game in skin regeneration.

IMPORTANT DISCLOSURES

The data in this report does not represent an investment or trading strategy. This material is for informational purposes only and should not be construed as an offer or solicitation to sell or buy any securities or for the acquisition or the subscription of shares in any fund or separately managed account. Any person in possession of this report should inform themselves with regard to the legal, fiscal, regulatory and foreign currency requirements for an investment in the fund according to the law of their home country, place of residence or current abode and seek expert, professional advice.

The information and opinions that are contained in this report have been compiled or arrived at by sources that are believed to be reliable and in good faith. However, the accuracy and completeness of this information is not expressively or implicitly guaranteed by this representation. Opinions contained in this presentation constitute judgment at the publish date of Blackcrane Capital, LLC (“Blackcrane”) and are subject to change without notice. This material is published for the assistance of recipients but is not to be relied upon as authoritative and is not to be substituted for the exercise of one’s own judgment.

Past performance does not guarantee future results. Returns and calculations are unaudited and may not be representative of past or future performance of an investment. The value of an investment can both increase and decrease, and investors face the risk of significant loss. This information should not be construed as research or investment advice. No representation or warranty is made, whether expressly or implied, by Blackcrane, its directors or employees, as to the accuracy or completeness of the information provided. This information is neither an offer to sell nor a solicitation of any offer to buy an interest in any fund or other investment vehicle sponsored or managed by Blackcrane.

Any decision to invest in a Blackcrane fund should be made only on the basis of consideration of all of the offering documents in respect of such a fund. These offering documents contain important information concerning risk factors and other material aspects of such a fund and must be read carefully before a decision to invest is made. Any account or fund advised by Blackcrane involves significant risks and is suitable only for those persons who can bear the economic risk of the complete loss of their investment. There can be no assurance that any account or fund will achieve its investment objectives. Please see Part II of Blackcrane’s Form ADV for more detail on risks, advisory fees, and other expense associated with the management of an investment advisory account.

INSTITUTIONAL INVESTOR USE ONLY

NLS 648 Exp. 06-30-2020